A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer

被引：0

作者：

Church, David N. ^{[1
]}

Price, Chris G. A. ^{[2
]}

机构：

[1] Univ Oxford, John Racliffe Hosp, Weatherall Inst Mol Med, Headley Way, Oxford OX3 9DS, England

[2] Bristol Haematol & Oncol Ctr, Bristol BS1 8ED, Avon, England

来源：

CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2009年 / 1卷

关键词：

breast cancer; trastuzumab; metastatic; ERBB2; HER2;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The ERBB2 or HER2 receptor is overexpressed in 25% of breast cancers and is associated with poor prognosis. Trastuzumab, a monoclonal antibody targeting HER2 has been demonstrated to improve survival when combined with chemotherapy for the treatment of HER2 overexpressing metastatic breast cancer (MBC). Further studies have endeavoured to clarify the optimum chemotherapy regimen in combination with trastuzumab for MBC and its use together with novel biological agents. This review summarises these data together with preclinical studies exploring the mechanism of trastuzumab action and causes of drug resistance. The frequent incidence of brain metastases in patients on trastuzumab is highlighted, and data on the continuation of trastuzumab following CNS and non-CNS progression reviewed.

引用

页码：557 / 570

页数：14

共 149 条

[41] ERBB-2 IS A POTENT ONCOGENE WHEN OVEREXPRESSED IN NIH/3T3 CELLS [J].

DIFIORE, PP ;

PIERCE, JH ;

KRAUS, MH ;

SEGATTO, O ;

KING, CR ;

AARONSON, SA .

SCIENCE, 1987, 237 (4811) :178-182

[42] Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J].

Ellis, MJ ;

Coop, A ;

Singh, B ;

Mauriac, L ;

Llombert-Cussac, A ;

Jänicke, F ;

Miller, WR ;

Evans, DB ;

Dugan, M ;

Brady, C ;

Quebe-Fehling, E ;

Borgs, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3808-3816

[43] Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells [J].

Esparis-Ogando, A. ;

Ocana, A. ;

Rodriguez-Barrueco, R. ;

Ferreira, L. ;

Borges, J. ;

Pandiella, A. .

ANNALS OF ONCOLOGY, 2008, 19 (11) :1860-1869

[44] Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer [J].

Esteva, FJ ;

Valero, V ;

Booser, D ;

Guerra, LT ;

Murray, JL ;

Pusztai, L ;

Cristofanilli, M ;

Arun, B ;

Esmaeli, B ;

Fritsche, HA ;

Sneige, N ;

Smith, TL ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1800-1808

[45] Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment [J].

Ewer, MS ;

Vooletich, MT ;

Durand, JB ;

Woods, ML ;

Davis, JR ;

Valero, V ;

Lenihan, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7820-7826

[46]

Extra JM, 2006, BREAST CANCER RES TR, V100, pS102

[47] Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies [J].

Fabi, Alessandra ;

Metro, Giulio ;

Ferretti, Gianluigi ;

Giannarelli, Diana ;

Di Cosimo, Serena ;

Papaldo, Paola ;

Mottolese, Marcella ;

Carlini, Paolo ;

Felici, Alessandra ;

Russillo, Michelangelo ;

Cognetti, Francesco .

BREAST, 2008, 17 (05) :499-505

[48]

FENDLY BM, 1990, CANCER RES, V50, P1550

[49] Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) [J].

Fountzilas, G ;

Christodoulou, C ;

Tsavdaridis, D ;

Kalogera-Fountzila, A ;

Aravantinos, G ;

Razis, E ;

Kalofonos, HP ;

Papakostas, P ;

Karina, M ;

Gogas, H ;

Skarlos, D .

CANCER INVESTIGATION, 2004, 22 (05) :655-662

[50] Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer - A Hellenic Cooperative Oncology Group phase II study [J].

Fountzilas, G ;

Tsavdaridis, D ;

Kalogera-Fountzila, A ;

Christodoulou, C ;

Timotheadou, E ;

Kalofonos, C ;

Kosmidis, P ;

Adamou, A ;

Papakostas, P ;

Gogas, H ;

Stathopoulos, G ;

Razis, E ;

Bafaloukos, D ;

Skarlos, D .

ANNALS OF ONCOLOGY, 2001, 12 (11) :1545-1551

← 1 2 3 4 5 6 7 8 9 10 →